Walter A. Wuillemin

Bern, BE, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Sustained Effectiveness of Lanadelumab in Preventing Hereditary Angioedema Attacks: The ENABLE Study.

Sustained Effectiveness of Lanadelumab in Preventing Hereditary Angioedema Attacks: The ENABLE Study.

Journal: Clinical and translational allergy

Published: January 28, 2026

Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER/ENABLE

Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER/ENABLE

Journal: Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)

Published: October 02, 2025

Authors' response.

Authors' response.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Published: September 25, 2025

Management of pregnancy, delivery and breast-feeding in hereditary angioedema: an analysis of 15 pregnancies with conventional treatment approaches and a case of Lanadelumab use.

Management of pregnancy, delivery and breast-feeding in hereditary angioedema: an analysis of 15 pregnancies with conventional treatment approaches and a case of Lanadelumab use.

Journal: Orphanet journal of rare diseases

Published: August 12, 2025

Lanadelumab's impact on hereditary angioedema control and quality of life across disease activity subgroups: Real-world evidence.

Lanadelumab's impact on hereditary angioedema control and quality of life across disease activity subgroups: Real-world evidence.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Published: May 16, 2025

Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort.

Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort.

Journal: Blood advances

Published: March 25, 2025

Management of common autoimmune diseases in patients with myeloproliferative neoplasms treated with pegylated interferon alfa-case report, review of the literature and multidisciplinary clinical practice recommendations.

Management of common autoimmune diseases in patients with myeloproliferative neoplasms treated with pegylated interferon alfa-case report, review of the literature and multidisciplinary clinical practice recommendations.

Journal: Therapeutic advances in hematology

Published: November 17, 2024

The dynamic range of immunoassays for heparin-induced thrombocytopenia.

The dynamic range of immunoassays for heparin-induced thrombocytopenia.

Journal: Journal of thrombosis and haemostasis : JTH

Published: July 01, 2024

Design-related bias in studies investigating diagnostic tests for venous thromboembolic diseases: a systematic review and meta-analysis.

Design-related bias in studies investigating diagnostic tests for venous thromboembolic diseases: a systematic review and meta-analysis.

Journal: Frontiers in cardiovascular medicine

Published: April 19, 2024

Accuracy of Diagnosing Heparin-Induced Thrombocytopenia.

Accuracy of Diagnosing Heparin-Induced Thrombocytopenia.

Journal: JAMA network open

Published: March 26, 2024

Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia.

Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia.

Journal: Blood advances

Published: January 26, 2024

Antithrombotic therapy and assessment for bleeding diathesis in elective gastrointestinal endoscopy - Expert Opinion Statement on behalf of the Swiss Society of Gastroenterology.

Antithrombotic therapy and assessment for bleeding diathesis in elective gastrointestinal endoscopy - Expert Opinion Statement on behalf of the Swiss Society of Gastroenterology.

Journal: Praxis

Published: January 09, 2024

Showing 1-12 of 59

Last Updated: 09/26/2026